Director, CMC Program Management - Drug Substance

About this role

Centessa Pharmaceuticals, a wholly subsidiary of Eli Lilly and Company is advancing a portfolio of high conviction programs with strong biological validation. Our asset-centric model offers a unique R&D logic that has been applied by single asset companies to improve productivity. This operating model has minimal centralized infrastructure, reduced hierarchy, and exclusive focus on data driven capital allocation. Our teams are uniquely incentivized to expeditiously interrogate key scientific hypotheses. We believe the asset-centric model can lead to improved success rates for programs with greater speed and modest costs.

Description of Role

Centessa is seeking a Director of CMC Program Management for Drug Substance. The CMC PM will provide leadership and operational support to the development and manufacturing of our small molecule programs and actively engage with internal teams and external contract manufacturing organizations. The individual will drive effective execution of CMC deliverables by the project teams in coordination with and support of program and corporate goals. The ideal candidate should be highly organized, well versed in project management tools and be an exceptional communicator with experience leading early phase pre-IND teams through late-stage CMC Registration/Commercial validation and launch activities. Travel to vendors both domestically and internationally will be required.

Key Responsibilities

• Partner closely with the CMC project lead to devise project strategic goals and drive these through seamless tactical execution.